REVIEW
Published on 09 Aug 2021
Viral Infection and Lung Cancer Immunotherapy
doi 10.3389/fonc.2021.577514
- 3,046 views
- 1 citation
- Frontiers in Oncology
- Thoracic Oncology
- Research Topics
- Issues and Challenges in NSCLC Immunotherapy
Issues and Challenges in NSCLC Immunotherapy
48k
Total downloads
161k
Total views and downloads
Articles
ORIGINAL RESEARCH
Published on 21 Jul 2021
Nivolumab in Non-Small Cell Lung Cancer: Real World Long-Term Survival Results and Blood-Based Efficacy Biomarkers
doi 10.3389/fonc.2021.625668
- 3,549 views
- 11 citations
ORIGINAL RESEARCH
Published on 27 May 2021
Absolute Lymphocyte Count Predicts Immune-Related Adverse Events in Patients With Non-Small-Cell Lung Cancer Treated With Nivolumab Monotherapy: A Multicenter Retrospective Study
doi 10.3389/fonc.2021.618570
- 4,372 views
- 19 citations
ORIGINAL RESEARCH
Published on 05 Mar 2021
Immune-Related Adverse Events and Their Association With the Effectiveness of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Real-World Study From China
doi 10.3389/fonc.2021.607531
- 3,789 views
- 28 citations
ORIGINAL RESEARCH
Published on 24 Feb 2021
A CT-Based Radiomics Approach to Predict Nivolumab Response in Advanced Non-Small-Cell Lung Cancer
doi 10.3389/fonc.2021.544339
- 3,469 views
- 30 citations
ORIGINAL RESEARCH
Published on 23 Feb 2021
Concordance of PD-L1 Status Between Image-Guided Percutaneous Biopsies and Matched Surgical Specimen in Non-Small Cell Lung Cancer
doi 10.3389/fonc.2020.551367
- 1,857 views
- 6 citations
SYSTEMATIC REVIEW
Published on 23 Feb 2021
The Impact of Programmed Death-Ligand 1 Expression on the Prognosis of Early Stage Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Literatures
doi 10.3389/fonc.2021.567978
- 2,315 views
- 10 citations
ORIGINAL RESEARCH
Published on 11 Feb 2021
nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)
doi 10.3389/fonc.2020.569715
- 4,250 views
- 3 citations
ORIGINAL RESEARCH
Published on 08 Feb 2021
Tissue MicroRNA Expression as a Predictor of Response to Immunotherapy in NSCLC Patients
doi 10.3389/fonc.2020.563613
- 2,734 views
- 15 citations
SYSTEMATIC REVIEW
Published on 11 Jan 2021
Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials
doi 10.3389/fonc.2020.574752
- 4,569 views
- 17 citations
MINI REVIEW
Published on 04 Dec 2020
The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors
doi 10.3389/fonc.2020.569202
- 3,556 views
- 26 citations
REVIEW
Published on 30 Nov 2020
Imperfect Predictors for Lung Cancer Immunotherapy—A Field for Further Research
doi 10.3389/fonc.2020.568174
- 2,317 views
- 16 citations
